Nuva Pharmaceuticals Inc (NUVPF) 0.1807 $NUVPF
VANC Pharmaceuticals Signs Definitive Agreement for Exclusive In-License on a CAD $150M Generic Molecule and soon to be Off Patent Molecule
Marketwired - Mon Jun 20, 7:02AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 20, 2016) - VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, pleased to announce that it has entered into a definitive agreement for filing two abbreviated new drug submissions (ANDS) with exclusive marketing rights to Canada from an unnamed, manufacturer. The manufacturing company is vertically integrated and manufactures these and other products from active pharmaceutical ingredient (API) to finished dosage forms. The manufacturer has USFDA and EU approved manufacturing facilities.
NPH.VN: 0.225 (-0.015)
Vanc Pharmaceuticals Announces Launch of New OTC Product and Provides Update on Sales Force Ramp Up
Marketwired - Mon May 02, 8:02AM CDT
Vanc Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("Vanc" or the "Company", a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that Health Canada has approved Cortivera(TM)-H (NPN: 80066699), a premium topical product for minor skin irritations. Cortivera(TM)-H has been approved for pharma care reimbursement program in the BC formulary, and is in the process to get listed in other provincial formularies.
NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Recognized as the Top Clean Technology & Life Sciences Company on the 2016 TSX Venture 50(TM)
Marketwired - Mon Jan 25, 7:31AM CST
Vanc Pharmaceuticals Inc. ("Vanc" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has been recognized in the 2016 TSX Venture 50 as the top performing Clean Technology & Life Sciences Company. The Company ranked number one in the sector.
NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Appointment of Mr. David Hall to Its Board of Directors
Marketwired - Thu Jan 21, 6:01AM CST
VANC Pharmaceuticals Inc. ("VANC" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce the appointment of Mr. David M. Hall to VANC's Board of Directors.
NPH.VN: 0.225 (-0.015)
Vanc Pharmaceuticals Launches First OTC Product in British Columbia
Marketwired - Mon Dec 07, 7:02AM CST
Vanc Pharmaceuticals Inc. ("Vanc" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commercialized its first OTC products in British Columbia: Cortivera(TM) and Cortivera Plus(TM) (Natural Product Number (NPN): 80037898) for a wide range of minor skin irritations, allergic reactions and eczema.
NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Commences Commercialization in Ontario
Marketwired - Thu Oct 22, 7:02AM CDT
VANC Pharmaceuticals Inc. ("VANC" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce that it has commenced commercialization of its generic drug portfolio in Ontario and has started shipping initial purchase orders to pharmacy customers in the province. Ontario represents $1.9 billion in generic drug sales on an annual basis, according to the Canadian Generic Pharmaceutical Association (CGPA).
NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Announces Listing of Products on Six Provincial Formularies in Canada
Marketwired - Wed Oct 07, 7:03AM CDT
VANC Pharmaceuticals Inc. ("VANC" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce that it has listed multiple products in Provincial formularies of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec.
NPH.VN: 0.225 (-0.015)
Vanc Pharmaceuticals Provides Corporate Update
Marketwired - Tue Sep 22, 7:04AM CDT
Vanc Pharmaceuticals Inc. ("Vanc" or the "Company"(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to provide a corporate update on the activities and progress of the Company over the past three months.
NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Commences Commercialization in British Columbia and Receives $1,095,728 in Proceeds From Warrant and Option Exercises
Marketwired - Wed Jul 08, 7:02AM CDT
VANC Pharmaceuticals Inc. ("VANC" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commenced commercialization of its generic drug portfolio in British Columbia (BC) and has started shipping initial purchase orders to pharmacy customers.
NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Announces Appointment of Mr. Bob Rai to its Board of Directors
Marketwired - Fri Jun 05, 7:01AM CDT
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company", a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce that Mr.Bob Rai has been appointed to the Company's Board of Directors effective immediately. Mr. Rai is a pharmacist with over 15 years of experience and is partner in a chain of The Medicine Shoppe Pharmacy (www.pharmacybc.com).
NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Announces Health Canada Approval for 5 New Generic Molecules and Provides Commercialization Update
Marketwired - Mon May 04, 7:02AM CDT
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company" is pleased to announce that it has received Drug Identification Numbers (DIN) from Health Canada for 5 new generic molecules as an initial notice of consent for new drug submissions. These 5 molecules will comprise of 14 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy.
NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Signs Definitive Agreement for Exclusive In-License on a CAD $150M Generic Molecule and soon to be Off Patent Molecule
Marketwired - Mon Jun 20, 7:02AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 20, 2016) - VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, pleased to announce that it has entered into a definitive agreement for filing two abbreviated new drug submissions (ANDS) with exclusive marketing rights to Canada from an unnamed, manufacturer. The manufacturing company is vertically integrated and manufactures these and other products from active pharmaceutical ingredient (API) to finished dosage forms. The manufacturer has USFDA and EU approved manufacturing facilities. NPH.VN: 0.225 (-0.015)
Vanc Pharmaceuticals Announces Launch of New OTC Product and Provides Update on Sales Force Ramp Up
Marketwired - Mon May 02, 8:02AM CDT
Vanc Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("Vanc" or the "Company"
, a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that Health Canada has approved Cortivera(TM)-H (NPN: 80066699), a premium topical product for minor skin irritations. Cortivera(TM)-H has been approved for pharma care reimbursement program in the BC formulary, and is in the process to get listed in other provincial formularies. NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Recognized as the Top Clean Technology & Life Sciences Company on the 2016 TSX Venture 50(TM)
Marketwired - Mon Jan 25, 7:31AM CST
Vanc Pharmaceuticals Inc. ("Vanc" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has been recognized in the 2016 TSX Venture 50 as the top performing Clean Technology & Life Sciences Company. The Company ranked number one in the sector. NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Appointment of Mr. David Hall to Its Board of Directors
Marketwired - Thu Jan 21, 6:01AM CST
VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce the appointment of Mr. David M. Hall to VANC's Board of Directors. NPH.VN: 0.225 (-0.015)
Vanc Pharmaceuticals Launches First OTC Product in British Columbia
Marketwired - Mon Dec 07, 7:02AM CST
Vanc Pharmaceuticals Inc. ("Vanc" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commercialized its first OTC products in British Columbia: Cortivera(TM) and Cortivera Plus(TM) (Natural Product Number (NPN): 80037898) for a wide range of minor skin irritations, allergic reactions and eczema. NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Commences Commercialization in Ontario
Marketwired - Thu Oct 22, 7:02AM CDT
VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce that it has commenced commercialization of its generic drug portfolio in Ontario and has started shipping initial purchase orders to pharmacy customers in the province. Ontario represents $1.9 billion in generic drug sales on an annual basis, according to the Canadian Generic Pharmaceutical Association (CGPA). NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Announces Listing of Products on Six Provincial Formularies in Canada
Marketwired - Wed Oct 07, 7:03AM CDT
VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce that it has listed multiple products in Provincial formularies of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec. NPH.VN: 0.225 (-0.015)
Vanc Pharmaceuticals Provides Corporate Update
Marketwired - Tue Sep 22, 7:04AM CDT
Vanc Pharmaceuticals Inc. ("Vanc" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to provide a corporate update on the activities and progress of the Company over the past three months. NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Commences Commercialization in British Columbia and Receives $1,095,728 in Proceeds From Warrant and Option Exercises
Marketwired - Wed Jul 08, 7:02AM CDT
VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commenced commercialization of its generic drug portfolio in British Columbia (BC) and has started shipping initial purchase orders to pharmacy customers. NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Announces Appointment of Mr. Bob Rai to its Board of Directors
Marketwired - Fri Jun 05, 7:01AM CDT
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company"
, a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce that Mr.Bob Rai has been appointed to the Company's Board of Directors effective immediately. Mr. Rai is a pharmacist with over 15 years of experience and is partner in a chain of The Medicine Shoppe Pharmacy (www.pharmacybc.com). NPH.VN: 0.225 (-0.015)
VANC Pharmaceuticals Announces Health Canada Approval for 5 New Generic Molecules and Provides Commercialization Update
Marketwired - Mon May 04, 7:02AM CDT
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company"
is pleased to announce that it has received Drug Identification Numbers (DIN) from Health Canada for 5 new generic molecules as an initial notice of consent for new drug submissions. These 5 molecules will comprise of 14 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy. NPH.VN: 0.225 (-0.015)
